Incidence of thrombosis in relapsed/refractory B-cell lymphoma treated with axicabtagene ciloleucel: Mayo Clinic experience-Reference-Cited by-同舟云学术

Incidence of thrombosis in relapsed/refractory B-cell lymphoma treated with axicabtagene ciloleucel: Mayo Clinic experience

Published:2022-02-03 Issue:6 Volume:63 Page:1363-1368
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Melody Megan¹,Gandhi Sangeetha²,Saunders Hollie¹,Abdel-Rahman Zaid³,Hastings Jacquelyn⁴,Lengerke Diaz Paula⁵,Gannon Nicole³,Truong Tuan²,Hathcock Matthew²,Khurana Arushi²,Johnston Patrick²,Ansell Stephen²,Bennani Nora²^ORCID,Paludo Jonas²^ORCID,Bisneto Jose Villasboas²^ORCID,Wang Yucai²,Rosenthal Allison⁵,Foran James³,Ayala Ernesto³,Murthy Hemant S.³,Roy Vivek³,Castro Januario E.⁵,Lin Yi²,Kharfan-Dabaja Mohamed A.³^ORCID

Affiliation:

1. Department of Internal Medicine, Mayo Clinic, Jacksonville, FL, USA

2. Division of Hematology, Mayo Clinic, Rochester, MN, USA

3. Division of Hematology-Oncology and Blood and Marrow Transplantation and Cellular Therapy Program, Mayo Clinic, Jacksonville, FL, USA

4. Department of Critical Care Medicine, Mayo Clinic, Jacksonville, FL, USA

5. Division of Hematology-Oncology and Blood and Marrow Transplantation, Mayo Clinic, Phoenix, AZ, USA

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2022.2030475